SK9492002A3 - A complex comprising osteoclastogenesis inhibitory factor and polysaccharide - Google Patents

A complex comprising osteoclastogenesis inhibitory factor and polysaccharide Download PDF

Info

Publication number
SK9492002A3
SK9492002A3 SK949-2002A SK9492002A SK9492002A3 SK 9492002 A3 SK9492002 A3 SK 9492002A3 SK 9492002 A SK9492002 A SK 9492002A SK 9492002 A3 SK9492002 A3 SK 9492002A3
Authority
SK
Slovakia
Prior art keywords
ocif
complex
group
variants
substance selected
Prior art date
Application number
SK949-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Shinichi Yamamoto
Junichi Okada
Atsushi Kurihara
Taku Numazawa
Junichi Kondo
Eisuke Tsuda
Shinichi Mochizuki
Hirotaka Nishi
Hideki Miyazaki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of SK9492002A3 publication Critical patent/SK9492002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK949-2002A 2001-06-29 2002-06-28 A complex comprising osteoclastogenesis inhibitory factor and polysaccharide SK9492002A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
SK9492002A3 true SK9492002A3 (en) 2003-02-04

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
SK949-2002A SK9492002A3 (en) 2001-06-29 2002-06-28 A complex comprising osteoclastogenesis inhibitory factor and polysaccharide

Country Status (22)

Country Link
US (3) US20030045456A1 (xx)
EP (1) EP1270015A3 (xx)
KR (1) KR20030003124A (xx)
CN (1) CN1442201A (xx)
AR (1) AR034716A1 (xx)
AU (1) AU783126B2 (xx)
BR (1) BR0202439A (xx)
CA (1) CA2392383A1 (xx)
CO (1) CO5390084A1 (xx)
CZ (1) CZ20022231A3 (xx)
HK (1) HK1048762A1 (xx)
HU (1) HUP0202119A2 (xx)
IL (1) IL150448A0 (xx)
MX (1) MXPA02006511A (xx)
NO (1) NO20023144L (xx)
PA (1) PA8549401A1 (xx)
PE (1) PE20030254A1 (xx)
PL (1) PL354799A1 (xx)
RU (1) RU2232594C2 (xx)
SG (1) SG98059A1 (xx)
SK (1) SK9492002A3 (xx)
ZA (1) ZA200205164B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
NZ511506A (en) 1998-10-28 2004-02-27 Sankyo Co Remedies for bone metabolic errors comprising OCIF
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
KR20040107492A (ko) 2002-04-10 2004-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US31725A (en) * 1861-03-19 Improvement in cultivators
US4207A (en) * 1845-09-27 lewis
US139325A (en) * 1873-05-27 Improvement in carriage-springs
TW318142B (xx) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
RU2203497C2 (ru) * 1997-09-24 2003-04-27 Санкио Компани Лимитед Способ диагностики метаболических костных заболеваний
DE69904818T2 (de) * 1998-06-15 2003-10-09 Takeda Chemical Industries Ltd Thienodipyridinderivate, ihre herstellung und verwendung
NZ511506A (en) * 1998-10-28 2004-02-27 Sankyo Co Remedies for bone metabolic errors comprising OCIF
EP1140136B1 (en) * 1999-09-03 2007-05-16 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica

Also Published As

Publication number Publication date
ZA200205164B (en) 2003-03-24
US20060084595A1 (en) 2006-04-20
BR0202439A (pt) 2003-06-10
MXPA02006511A (es) 2004-08-11
US20030139325A1 (en) 2003-07-24
HUP0202119A2 (hu) 2003-04-28
US20030045456A1 (en) 2003-03-06
AU5071902A (en) 2003-01-02
KR20030003124A (ko) 2003-01-09
NO20023144L (no) 2002-12-30
PL354799A1 (en) 2002-12-30
CZ20022231A3 (cs) 2003-02-12
SG98059A1 (en) 2003-08-20
RU2002117385A (ru) 2004-01-27
CA2392383A1 (en) 2002-12-29
HU0202119D0 (xx) 2002-08-28
IL150448A0 (en) 2002-12-01
EP1270015A3 (en) 2004-02-25
RU2232594C2 (ru) 2004-07-20
NO20023144D0 (no) 2002-06-28
CO5390084A1 (es) 2004-04-30
AU783126B2 (en) 2005-09-29
PE20030254A1 (es) 2003-03-19
HK1048762A1 (zh) 2003-04-17
AR034716A1 (es) 2004-03-17
CN1442201A (zh) 2003-09-17
EP1270015A2 (en) 2003-01-02
PA8549401A1 (es) 2003-07-28

Similar Documents

Publication Publication Date Title
EP3154566B1 (en) Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
US20060084595A1 (en) Complex comprising OCIF and polysaccharide
EP2763689B1 (en) Fibroblast growth factor 21 variants
JP5334347B2 (ja) 化学的に修飾した新規なエリスロポエチン刺激タンパク質組成物および方法
EP1121155B1 (en) Site-directed dual pegylation of proteins
AU623447B2 (en) Binding protein for insulin-like growth factors
AU2016201712A1 (en) ActRIIb antagonists and dosing and uses thereof
JP2006512326A (ja) 心臓疾患におけるエリスロポエチンの新規な使用
JP2012530493A (ja) キメラポリペプチドおよびその使用
TW200927758A (en) Variants of C-type natriuretic peptide
AU2014221534B2 (en) Site-specific insulin conjugate
Collier et al. O-linked oligosaccharides on insulin receptor
EP1008603B1 (en) Soluble polypeptides consisting on the first coiled coil domain of human and mouse epimorphin.
JP6464145B2 (ja) 成長ホルモン化合物製剤
JPH11500904A (ja) Ｍｐｌリガンド類似体
US20030216297A1 (en) Pharmaceutical composition
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
AU658187B2 (en) Human bone derived insulin like growth factor binding protein
JP2004203747A (ja) 破骨細胞形成抑制因子を含有する治療剤
JP2004059582A (ja) 骨破壊の治療または予防剤組成物の併用効果
CA2368937A1 (en) Prevention of brain damage in stroke
JP2003160601A (ja) 破骨細胞形成抑制因子を含有する複合体
US6329500B1 (en) Transforming growth factor-β binding site
MXPA01003764A (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JPH1080277A (ja) 変異型ヒト成長ホルモンとその用途

Legal Events

Date Code Title Description
FC9A Refused patent application